Share on StockTwits

Ligand Pharmaceuticals (NASDAQ:LGND) Director Melanie J. Herman unloaded 1,100 shares of the company’s stock on the open market in a transaction dated Monday, June 9th. The stock was sold at an average price of $69.68, for a total transaction of $76,648.00. Following the completion of the transaction, the director now directly owns 2,630 shares in the company, valued at approximately $183,258. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Analysts at Brinson Patrick initiated coverage on shares of Ligand Pharmaceuticals in a research note on Monday, March 24th. They set an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.74.

Ligand Pharmaceuticals (NASDAQ:LGND) traded up 0.84% on Tuesday, hitting $69.22. The stock had a trading volume of 143,404 shares. Ligand Pharmaceuticals has a 1-year low of $30.85 and a 1-year high of $80.42. The stock’s 50-day moving average is $65.58 and its 200-day moving average is $63.72. The company has a market cap of $1.435 billion and a price-to-earnings ratio of 117.74.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.10. The company had revenue of $16.00 million for the quarter, compared to the consensus estimate of $13.63 million. The company’s quarterly revenue was up 36.8% on a year-over-year basis. Analysts expect that Ligand Pharmaceuticals will post $1.44 EPS for the current fiscal year.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.